Barclays raised the firm’s price target on Abbott (ABT) to $149 from $143 and keeps an Overweight rating on the shares. After rallying on the heels of the favorable jury verdict last week, the firm revisited its bullish investment thesis on Abbott.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $149 from $143 at Barclays
- Reckitt and Abbott Shares Rally on Baby Formula Lawsuit Win
- Morning Movers: Apple dips, Amazon gains after earnings
- Abbott, Mead Johnson secure win in infant formula trial, Reuters reports
- Raymond James says Edwards’ EARLY TAVR data also positive for Medtronic, Abbott